CBLL Q1 2026 Earnings Call Summary

Ceribell Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $26.5 million, up 29% year-over-year and 7% sequentially.
Product Revenue: $20.2 million, a 29% increase from $15.6 million in Q1 2025.
Subscription Revenue: $6.3 million, up 29% from $4.9 million in Q1 2025.
Gross Margin: 87%, slightly down from 88% in the prior year.
Operating Expenses: $43.9 million, a 36% increase from $32.2 million in Q1 2025, primarily due to higher sales and marketing costs and litigation expenses.
Net Loss: $19.7 million, or $0.52 per share, compared to a loss of $12.8 million or $0.36 per share in Q1 2025.
Adjusted EBITDA Loss: $11.2 million, compared to $10.9 million in Q1 2025.
Cash Position: $141.2 million as of March 31, 2026.

2. Strategic Updates and Business Highlights

Account Growth: Ceribell added 33 new accounts, bringing the total to 680 hospitals, marking the strongest quarter of account growth since going public.
Product Launches: Full commercial launch of neonate and pediatric seizure monitoring products initiated, with positive feedback from pilot sites.
Delirium Pilot: Activated the first site for a delirium monitoring pilot, aiming to establish EEG as a new vital sign in ICU settings.
Market Expansion: Continued penetration into the VA system and initiated a pilot at military hospitals, leveraging previous successes.
Clinical Validation: Positive early feedback from pediatric and neonate programs, with significant clinical and health economic drivers observed.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Updated to a range of $112 million to $116 million, reflecting a growth of 26% to 30% over 2025.
Gross Margin Expectation: Anticipated to remain in the high 80% range for the remainder of 2026, aided by lower tariff rates from inventory sourced in Vietnam.
Long-Term Vision: Aiming to establish EEG as a standard of care for seizure management with a total addressable market estimated at $3.5 billion in the U.S.

4. Bad News, Challenges, or Points of Concern

Operating Expenses: Increased significantly, particularly due to litigation costs ($5.6 million), which are expected to remain elevated in the near term.
Seasonality: Anticipated sequential moderation in Q2 and Q3 volumes due to reduced ICU census during warmer months, which could impact revenue.
Net Loss: The increase in net loss raises concerns about profitability timelines, despite strong revenue growth.

5. Notable Q&A Insights

Sales Force Productivity: Over 85% of territory managers with over 12 months of tenure contributed to the account base, indicating effective hiring and training processes.
Delirium and Seizure Monitoring Synergy: Clinical overlap between seizure and delirium monitoring was discussed, with potential for cross-utilization in hospitals.
Military Hospitals: The pilot program at military hospitals is seen as a significant but smaller opportunity compared to the VA network.
Utilization Trends: Strong utilization trends were noted, with ongoing departmental expansion efforts contributing to increased patient monitoring.

Overall, Ceribell's Q1 2026 results reflect strong revenue growth and strategic advancements, despite challenges related to operating expenses and seasonal revenue fluctuations. The company remains optimistic about its future trajectory and market potential.

CBLL — CeriBell, Inc.